Drugs / Dual CD33/CLL1 CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05248685 | Feb 2022 → Dec 2023 | acute myeloid leukemia | Beijing Boren Hospital | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dual CD33/CLL1 CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05248685 ↗ |
| Modality | Cell therapy | “infusion of CAR T cells” NCT05248685 ↗ |
| Target | CD33 | “Dual CD33/CLL1 CAR T Cells” NCT05248685 ↗ |